Fig. 3: Acute inhibition of Arc neurons on T1D glucose.
From: A neural basis for brain leptin action on reducing type 1 diabetic hyperglycemia
AgRP-Cre or Vgat-Cre mice were injected with AAV-DIO-h4MD(Gi)-mCherry vectors to bilateral Arc and then were made STZ-T1D. a–c Series of sections spanning the Arc showing specific expression of viral vector expression (red) and c-Fos expression (green) in mistargeted mice (a), AgRP-Cre (b), and Vgat-Cre mice (c). Representative pictures over 3 repeats. d–f Comparisons in blood glucose in the indicated groups of mice in response to a 3-day CNO treatment protocol (twice daily for 3 days) (d, two-way ANOVA, n = 5/each, F(2, 75) = 16.41, *P < 0.0001, AgRP-Gi-DREADD vs Vgat-Cre-Gi-DREADD at day 3; *P < 0.0001, missed vs Vgat-Cre-Gi-DREADD at day 3), comparisons in corticosterone (e, one-way ANOVA, n = 5/each, F(2, 12) = 1.449, P = 0.4774, missed vs Vgat-Cre-Gi-DREADD at day 3) and glucagon (f, one-way ANOVA, n = 5/each, F(2, 12) = 18.93, ***P = 0.0005, Vgat-Gi-DREADD vs missed; ***P = 0.0005, Vgat-Gi-DREADD vs AgRP-Gi-DREADD) at day 3 after the initiation of CNO treatment. 3V the third ventricle, Arc arcuate nucleus. All data presented as mean ± SEM. Scale bar: 100 µM.
